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AbstrACt
Introduction Most people suffering from depression and 
anxiety disorders are entirely treated in primary care. Due 
to growing challenges in ageing societies, for example, 
patients’ immobility and multimorbidity, the transition to 
specialised care becomes increasingly difficult. Although 
the co-location of general practitioners and mental health 
specialists improves the access to psychosocial care, 
integrated in-person approaches are not practical for rural 
and single-doctor practices with limited personnel and 
financial resources. Treating primary care patients via 
internet-based video consultations by remotely located 
mental health specialists bears the potential to overcome 
structural barriers and provide low-threshold care. The 
aim of this randomised controlled feasibility trial is to 
investigate the feasibility of implementing of mental 
health specialist video consultations in primary care 
practices.
Methods and analysis Fifty primary care patients with 
significant depression and/or anxiety symptomatology 
will be randomised in two groups receiving either the 
treatment as usual as provided by their general practitioner 
or up to five video consultations conducted by a mental 
health specialist. The video consultations focus on (1) 
systematic diagnosis plus proactive monitoring using 
validated clinical rating scales, (2) the establishment of an 
effective working alliance and (3) a stepped-care algorithm 
within integrated care adjusting treatments based on 
clinical outcomes. We will investigate the following 
outcomes: effectiveness of the recruitment strategies, 
patient acceptance of randomisation, practicability of the 
technical and logistical processes related to implementing 
video consultations in the practices’ workflows, feasibility 
of the data collection and clinical parameters.
Ethics and dissemination This trial has undergone 
ethical scrutiny and has been approved by the Medical 
Faculty of the University of Heidelberg Ethics Committee 
(S-634/2018). The findings will be disseminated to the 
research community through presentations at conferences 
and publications in scientific journals. This feasibility trial 
will prepare the ground for a large-scale, fully powered 
randomised controlled trial.
trial registration number DRKS00015812.
IntroduCtIon
Depression and anxiety disorders are highly 
prevalent, cause a substantial disease burden 
and account for the two highest numbers of 
disability-adjusted life years among all mental 
disorders.1 2 Most patients with depression 
and anxiety disorders are treated in primary 
care, which has evolved as the crucial point of 
mental healthcare in many high-income coun-
tries.3 However, while general practitioners 
(GPs) generally provide comprehensive care 
to most of their patients, a significant number 
of people, especially those with somatic 
comorbidities, suffering from mental health 
conditions do not get adequate treatment.4 
This problem is aggravated by patient-related 
and system-related determinants. The access 
to specialised mental healthcare is impeded 
by long waiting times at the provider’s end 
along with older patients’ immobility due 
to increasing multimorbidity in an ageing 
society.5 Multimorbidity in turn constitutes 
a challenge for GPs who are often obligated 
to emphasise the assessment and treat-
ment of somatic symptoms due to guideline 
strengths and limitations of this study
 ► This is one of the first feasibility trials investigating 
mental health specialist video consultations for pa-
tients presenting in primary care.
 ► While gathering comprehensive multimodal data 
on feasibility outcomes, we will also longitudinally 
assess the development of the conversation quality 
and the therapeutic alliance in the course of the vid-
eo consultations.
 ► Given the nature of our feasibility study, we will not 
be able to determine intervention effectiveness at 
this point, but our findings will inform the design of 
a sufficiently powered randomised controlled trial.
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recommendations.6 However, for GPs, prioritising somatic 
work-up and treatment conflicts with devoting their time 
and attention to psychosocial aspects.7
To resolve these challenges, it is essential to develop 
healthcare models that combine the easily accessible envi-
ronment of primary care and the expertise in timely diag-
nostics and therapy of a mental health specialist (MHS). 
These models may help providing a tailored treatment 
for patients initially presenting to their GP. Indeed, two 
principal approaches for fostering the co-operation and 
co-ordination between GPs and MHS have evolved. In 
the Collaborative Care (CC) model, the GP is supported 
by a case manager who tracks patients per telephone, 
conducts psychological assessments and presents the data 
to an MHS, often a psychiatrist. The MHS monitors the 
patients and intervenes, if necessary, by prescribing drugs 
or scheduling face-to-face contacts. This time-saving 
model reaches a higher number of patients in specialised 
mental care than the usual referral-based system as the 
MHS is not required to see all patients regularly.8 The 
Primary Care Behavioural Health (PCBH) model co-lo-
cates the primary care team and the MHS.9 10 Specifically, 
the MHS provides “high volume services that are acces-
sible, team-based, and a routine part of primary care”.10 
For example, at Cherokee Health Systems, a complete 
community health system in Tennessee in the USA 
(https://www. cherokeehealth. com/), MHS engage in 
goal setting together with patients, in patient activation 
and in psychosocial care.11 Often MHS attend to patients 
through warm hand-offs instead of receiving conventional 
referrals. This model provides a low-threshold access to 
specialised care and has been well accepted in patients 
and providers.
Both CC and PCBH have been implemented success-
fully in the US healthcare system.12 However, even in the 
USA, where the mean number of primary care physicians 
per practice is much higher than in European countries, 
such as the UK, France and Germany, small and remote 
practices especially in rural areas often do not have the 
resources to employ an additional MHS.13 Consequently, 
these barriers are even higher in healthcare systems where 
smaller practices (with one or two doctors) with rather 
limited resources predominate. It is crucial to investigate 
potentially more feasible modes for putting these inte-
grated care models into practice.
As an innovative, technology-supported approach to 
integrated care, real-time video consultations conducted 
by MHS are increasingly considered to be an alterna-
tive to in-person settings. Systematic reviews point to the 
general effectiveness of telemedicine interventions for 
mental health conditions.14–16 Concerning the integra-
tion of telepsychiatry services in primary care as such, 
several observational and interventional studies demon-
strate that mental health specialist video consultations 
(MHSVCs) contribute to overcoming geographical 
barriers and to treating the increasing number of multi-
morbid patients often cut off from specialised care.17–20 
However, the randomised controlled trials (RCTs) were 
conducted in selected healthcare settings (US Veterans 
Healthcare Administration, Rural Federally Qualified 
Health Centers) and therefore their results are of limited 
generalisability, for example, to European healthcare 
systems.17 18 Nevertheless, patients may benefit from 
timely access to specialised care, less stigmatisation, 
more personal proximity compared with self-help and 
telephone interventions, and better compatibility with 
work-related or domestic obligations in the light of 
reduced travel times.21
The junior research group PROVIDE (ImPROving 
cross-sectoral collaboration between primary and psycho-
social care: An implementation study on VIDEo consul-
tations) aims to define, tailor and evaluate an integrated 
care model compatible with small and/or remote GP 
offices where the patient will receive the telemedical 
service. In contrast, the MHS will be situated in her or 
his office/private practice or a suitable, designated room 
at home. The project is funded by the German Ministry 
of Education and Research and culminates in a large-
scale RCT. In this protocol, we describe a randomised 
controlled feasibility trial, which will assess the feasibility 
of research methods and the intervention: mental health 
specialist video consultations in primary care.
MEthods And AnAlysIs
study design
This study is a multicentric, prospective, assessor blinded 
and individually randomised controlled feasibility trial. 
After inclusion of patients, the individual intervention 
period will be 3 months; the total time of recruitment is 
planned to be 6 months. There will be two measurements 
including a baseline assessment just prior to randomis-
ation and post-assessment at 4 months after inclusion. 
The study will be implemented and reported in line with 
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines22 (online supple-
mentary appendix 1).
sample size
We project a target sample size of 50 participants. Since 
the aim of this study is to establish feasibility of a full trial, 
but no detection of statistically significant difference in 
efficacy between the arms, a formal sample size calculation 
was not carried out. A sample size of 50 patients offers a 
reasonable test of the intervention to assess the feasibility 
objectives. This sample size is also recommended for pilot 
and feasibility trials by The National Institute for Health 
Research.23 24
recruitment
General practitioners
In this feasibility study, four family practices will be 
recruited. Each practice then will recruit approximately 13 
patients. Access to them will be sought first by contacting 
GPs who participated in a preceding qualitative pre-im-
plementation study and second through the network of 
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collaborating academic research practices affiliated with 
the Department of General Practice and Health Services 
Research at Heidelberg University. During on-site 
visits, we will inform the practice teams about the study 
including the concomitant process evaluation and the 
assessments involved. We will also test the quality of the 
internet connexion to evaluate the eligibility. The partici-
pation requires the signed informed consent.
Mental health specialists
Recruitment of the therapists will be conducted at the 
Institute for Psychotherapy, Heidelberg (HIP), which 
is a state-approved psychotherapeutic training facility 
at Heidelberg University Hospital. We will recruit four 
psychotherapists or psychotherapy trainees, that is, 
psychologists in the advanced training period, in total, 
one for each general practice. We will contact all lecturers 
(mostly licensed psychotherapists) and trainees systemat-
ically using the respective mailing lists. Interested indi-
viduals will have to apply and will then be invited for a 
short interview. The final decisions on the participating 
psychotherapists will be made by mutual discussion and 
consensus formation in the study team. The MHS will 
participate in the study as freelancers and will be paid per 
session according to the current fees for psychotherapy 
as reimbursed by the German statutory health insurance. 
For the therapists, expected time expenditure will be 
approximately 6 hours per week (4 hours for consulta-
tions, 1.5 hours for supervision).
Patients
GPs will recruit patients during their regular clinic hours. 
Based on their clinical judgement, GPs will prospectively 
select individuals suspected to suffer from depression or 
anxiety and present the study to them by offering infor-
mation material. If the patient agrees to receive more 
information, she or he will be contacted by the study team 
who will screen her or him with respect to the eligibility 
criteria. We will send a hard-copy version of the study 
information booklet and the informed consent form to 
all the patients interested in participation. At this point, 
patients will be able to raise questions with the prin-
cipal investigator. Study participation requires a signed 
informed consent which the patients will mail back to 
the trial co-ordination centre. Whenever inclusion is not 
possible, we will record the reason, the recruiting general 
practice along with patient age and gender.
Inclusion and exclusion criteria
Patients
Inclusion criteria require patients to (1) exceed cut-offs 
of 9 points (a) for the Patient Health Questionnaire 
(PHQ-9) and/or (b) for the Generalized Anxiety 
Disorder 7 (GAD-7),25 respectively, (2) currently have no 
or as yet insufficient treatment (psychotherapy, psycho-
pharmacotherapy or both) or difficulty with adherence, 
(3) agree to participate in the study by written informed 
consent, (4) be capable of giving consent and (5) be 
18 years or older. Exclusion criteria are as follows: (1) 
substance abuse/dependence that is likely to compro-
mise intervention adherence; (2) risk of endangerment 
to others and/or risk of self-endangerment; (3) need for 
emergency medical treatment, for example, admission; 
(4) acute psychotic symptoms, for example, persecutory 
delusions and/or thought insertion; (5) severe cognitive 
impairment or dementia; (6) significant hearing and/or 
visual impairment; (7) pregnancy in the ≥2nd trimester; 
(8) insufficient German language proficiency.
Primary care practices and mental health specialists
Inclusion criteria for practices are as follows: (1) primary 
practice (specialist in general medicine or internal 
medicine), (2) team that familiarises patients with video 
consultations and (3) written informed consent. Exclu-
sion criteria for the practices are lack of a designated 
room for the video consultations to ensure confidentiality 
and lack of internet access or low bandwidth (<384 kbps).
Participating MHS must be licensed psychotherapists 
or advanced trainee in psychotherapy (that is, at least 
1200 hours of treatment experience) and give written 
informed consent.
randomisation
Patients will be randomly allocated to one of the two study 
conditions (video consultation model vs treatment-as-
usual) in a 1:1 ratio. After having obtained the informed 
consent, the randomisation will be conducted centrally at 
the study centre. The web-based application Randomizer 
V.2.0.2 of the Institute for Medical Informatics, Statistics 
and Documentation of the Medical University of Graz, 
Austria (https://www. randomizer. at) will be used, which 
ensures the concealment of the treatment sequence up 
to the allocation by central randomisation. The treat-
ment sequence is generated through a computer-gener-
ated sequence of random numbers. We will apply block 
randomisation with stratification of patients by office. A 
member of the Institute of Medical Biometry and Infor-
matics, Heidelberg University, not involved in the patient 
recruitment will randomise. We will ensure that the asses-
sors who will collect the data will be blinded to the allo-
cated treatment.
study procedures
During an introductory training, we will familiarise the 
therapists and supervisors participating in the study and 
cover (1) an introduction to the research project, (2) a 
detailed description of the study procedures, (3) a step-
by-step instruction on the handling of video consultations 
(eg, room setup and technical aspects), (4) an introduc-
tion to the intervention and (5) a familiarisation with 
the respective general practice.26–30 For enrolling and 
preparing practices, study team members will visit each 
practice twice. During the first visit, we will check for a 
designated room suitable for confidential video consulta-
tions, enough bandwidth and technical equipment. If the 
practice is eligible, we will conduct a second visit during 
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Figure 1 Study flowchart. GP, general practitioner; MHS, 
mental health specialist.
which we will (1) explain the study procedures in greater 
detail, (2) obtain informed consent from the practice 
team, (3) introduce the assigned therapist personally, 
(4) prepare the technical equipment, (5) train the GP in 
expense presenting the study to patients (eg, by dispensing 
jointly designed brochures and positioning waiting room 
posters both tailored to the respective practice) and (6) 
clarify the regular time slots for the consultations. We will 
train all clinicians in initiating the consultations logis-
tically and technically drawing on the latest guidance 
available.27 To mitigate potential insecurities, we will 
also inform the clinicians that there is currently “[…]
no evidence to suggest prohibiting trainees or clinicians 
from engaging in telehealth if they are otherwise quali-
fied”.31 We will ensure that every practice will nominate 
one team member who will be responsible for initiating 
video consultations and who will serve as contact person 
for MHS, patients and the study team. Applying a training 
that primarily targets technical competency, we are confi-
dent that we will minimise potential difficulties with 
handling video consultations and consequently minimise 
task-related expenses. In fact, technical competency is 
regarded as crucial for successfully implementing telepsy-
chiatry services.32 Additionally, we will address remaining 
questions and equip the teams with a study handbook 
including description of the secure videoconferencing 
platform and contingency plans in case of technical fail-
ures. GPs will then start recruiting patients by forwarding 
their contact information to the study team. To screen 
patients using the PHQ-9 and GAD-7, the study team will 
conduct standardised computer-assisted telephone inter-
views. After providing written informed consent, patients 
will fill out the baseline questionnaire and mail it back to 
the trial co-ordination centre. Patients will be randomly 
allocated to the intervention or the control condition. 
The study flow is depicted in figure 1.
Intervention
The PROVIDE intervention is a targeted primary care–
based mental health service that combines elements of 
the collaborative care and consultation-liaison model. 
Specifically, the intervention features web-based, real-
time video consultations involving a live two-way interac-
tive video to a primary care practice between MHS and 
patients. The intervention includes three core processes 
(‘active ingredients’) for effective primary care–based 
mental healthcare, namely systematic diagnosis plus 
proactive monitoring using validated clinical rating scales, 
the establishment of an effective working alliance and a 
stepped-care algorithm within integrated care adjusting 
treatments based on clinical outcomes. If indicated, the 
PROVIDE intervention also includes brief psychological 
therapy that works with interpersonal dynamics and that 
has been shown to confer additional benefit.33 The inter-
vention follows a transdiagnostic treatment approach 
for emotional disorders(depression and anxiety), for 
which various meta-analyses have shown the efficacy 
compared with control conditions on measures of overall 
anxiety, disorder-specific anxiety and depression.34 35 
Specifically, the intervention combines elements from 
problem-solving therapy, which has been shown to yield 
moderate effects in alleviating depression and anxiety 
in primary care.36 Psychodynamic elements following 
a relationship focus and interpersonal understanding 
are added to foster the working alliance that has been 
promoted as a crucial element of manuals achieving high 
acceptability in both patient and clinicians.37 In line with 
a stage model of psychotherapy manual development,38 
we compiled a stage I intervention manual delineating 
treatment techniques, goals and format (supplemen-
tary appendix 2). For a description of the interven-
tion, we followed the TIDieR checklist (supplementary 
appendix 3).39
Patients will receive their first video consultation 
shortly after randomisation and will be scheduled for up 
to five sessions, lasting 50 min each, in biweekly intervals. 
The video consultations will be carried out on a secure 
(ie, encrypted), web-based videoconferencing platform 
on a subscription basis (arztkonsultation ak GmbH, 
https:// arztkonsultation. de) at the fixed time slots set 
by the general practice staff. The patient will be in the 
general practice and the psychotherapist either in her 
or his office/private practice, in a suitable, designated 
room at home or in a therapy room at the HIP. Each 
MHS is permanently assigned to one general practice. 
At the beginning of each consultation, a practice team 
member will escort the patient to the room designated 
for video consultations, set up the computer tablet and 
the videoconferencing platform, if applicable, address 
the patient’s questions and then leave the room. After the 
third session, we will conduct an interim evaluation of the 
Protected by copyright.
 o
n
 N
ovem
ber 4, 2019 at Radboud University Nijmegen.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030003 on 4 September 2019. Downloaded from 
5Tönnies J, et al. BMJ Open 2019;9:e030003. doi:10.1136/bmjopen-2019-030003
Open access
Figure 2 Study schedule.22 1. Patient Health Questionnaire 
9 (PHQ-9),25 Generalised Anxiety Disorder Scale (GAD-
7),25 Recovery Assessment Scale (RAS-G),40 EQ-5D,41 
Somatic Symptom Disorder–B Criteria Scale (SSD-12).42 
2. Questionnaire for the Assessment of Medical and 
non-Medical Resource Utilisation in Mental Disorders 
(FIMPsy).45 3. Inventory for the Assessment of Negative 
Effects of Psychotherapy (INEP).46 4. Normalisation MeAsure 
Development (NoMAD) questionnaire.49 GP, general 
practitioner; MHS, mental health specialist.
symptoms (using PHQ-9 and GAD-7) and feedback these 
results to the therapist. After the last consultation with 
the patient, the MHS will send a written case summary 
to the GP which will be attached to the medical record 
in the primary care practice and on which, if needed, 
further decisions on follow-up procedures between GPs 
and MHS can be based.
The study therapists, psychologists with a diploma or 
master’s degree or medical doctors, will be required to 
be trained in psychodynamic psychotherapy or cogni-
tive-behavioural therapy for at least 3 years. Parallel to the 
study, they will receive weekly group supervision led by a 
senior consultant both in psychiatry and psychosomatic 
medicine from the Department of General Practice and 
Psychosomatics, Heidelberg University.
Control condition
Patients allocated to the control group will get the usual 
care provided by the GP. This may or may not include 
a referral to an MHS. We expect that most people with 
depression and/or anxiety disorders are currently treated 
by their GP only. GPs rather provide brief counselling and 
prescribe psychotropic medication than conduct psycho-
therapy as laid out in guidelines. Only every fifth patient 
with depression is referred to specialised care.5 There will 
not be any restrictions to the usual treatment by the GP.
Measurements
Patients’ health status
For patients, the baseline assessment will take place 
before randomisation and include a set of validated ques-
tionnaires: PHQ-9,25 GAD-7,12 German version of the 
Recovery Assessment Scale,40 EQ-5D,41 Somatic Symptom 
Disorder–B Criteria Scale42 and Patient Assessment of 
Chronic Illness Care.43 Following the Medical Research 
Council guidance on developing and evaluating complex 
interventions,44 a health-economic evaluation is planned 
for the main trial. Hence, a questionnaire on the use of 
services is part of the assessment instruments.45 Post-mea-
surements will be scheduled 4 months after inclusion in 
the study and will include the same measures as well as 
the Inventory for the Assessment of Negative Effects of 
Psychotherapy for measuring potential adverse effects.46 
As part of the blind outcome assessment, two research 
assistants, blinded to participant allocation, will conduct 
the post-measurement in telephone interviews with the 
participants. In line with current recommendations, we 
specifically will make sure that the outcome assessors will 
not be present when discussing individual patients and 
avoid mentioning any names or assigned treatments.47 
In addition, we will instruct patients before the interview 
not to mention which group, control or intervention, 
they belonged to. In the case of unintentional unblinding 
during the assessment, the assessors will document how 
and at which point the unblinding unfolded. Hence, we 
will be able to subsequently determine the extent to which 
blinded assessment was successful. The study schedule is 
depicted in figure 2 in line with the SPIRIT guidelines.
Feasibility
To assess process feasibility from the patients’ perspective, 
we will conduct semi-guided qualitative interviews with 
10 purposefully selected patients from the intervention 
group stratified by practice site, patient age and patient 
technology commitment. By applying this criterion, we 
aim for maximising the transferability of our feasibility 
findings, for example, with respect to compatibility with 
existing clinical workflows. To evaluate the acceptability 
of both study and intervention procedures, we will analyse 
patients’ perceptions whether the intervention and study 
procedures have been agreeable as well as logistically and 
technically practical.48
As part of a pre–post-study measurement of feasibility, 
all practice teams and MHS will fill out the Normalisation 
MeAsure Development (NoMAD) questionnaire49 prior 
to inclusion of the first patient and close-out of the last 
patient. This questionnaire assesses providers’ and staffs’ 
perceptions of factors relevant to embedding interven-
tions that change their work practices. Furthermore, as 
part of the post-measurement, all GPs, all team members 
responsible for initiating video consultations and all MHS 
Protected by copyright.
 o
n
 N
ovem
ber 4, 2019 at Radboud University Nijmegen.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030003 on 4 September 2019. Downloaded from 
6 Tönnies J, et al. BMJ Open 2019;9:e030003. doi:10.1136/bmjopen-2019-030003
Open access 
will participate in individual qualitative semiguided inter-
views to describe feasibility, adequacy and acceptance of 
the proposed model in greater detail. To estimate the 
conversation quality of the video consultations, patients 
and MHS will complete the 8-item Telepresence in Video-
conference Scale at the end of each consultation.50 This 
instrument assesses the subjective feeling of presence in 
psychotherapy accounting for the three factors physical 
presence, social presence and absorption. From these 
high-frequency repeated measurements, we aim to docu-
ment the level of stability in the quality of the consul-
tations (eg, habituation effects, ruptures during the 
intervention).
outcomes
To determine the feasibility of a subsequent large-scale 
RCT, we will assess the following outcomes and aspects:
 ► Sufficiency and efficiency of recruitment strategies for 
intervention and control group
 ► Recruitment and attrition rates for intervention and 
control group
 ► Patient and provider acceptance of outcome 
measurements.
 ► Feasibility of study procedures (eg, patient and 
provider acceptance of randomisation and outcome 
measurements).
 ► Feasibility of intervention procedures (including the 
necessary documentation, implementation loyalty, 
patient acceptance of video consultations, patient 
safety).
We will operationalise the sufficiency of recruiting 
strategies and the acceptance of randomisation and by 
measuring recruitment and retention rates, including 
recruitment patterns from each route and geograph-
ical area. We will ask patients declining to participate or 
dropping out to provide their reasons for doing so. With 
respect to process outcomes on the overall practicability 
of the intervention and the related study procedures, we 
will draw on qualitative data generated by in-depth inter-
viewing of patients, practice staff and MHS.
data analysis
To promote data quality, data management procedures 
will include double data entry and a comprehensive plau-
sibility check (eg, concerning range of data values). Only 
the first and the corresponding author will have access 
to the final trial dataset. Quantitative data regarding the 
feasibility of a following large-scale RCT, for example, 
recruitment rates and attrition at study completion, along 
with health outcomes from questionnaires will be anal-
ysed applying descriptive statistics (absolute and relative 
frequencies, measures of central tendency and measures 
of variability). Specifically, the number of potential partic-
ipants contacted, screened and included will be reported. 
The percentages of potential participants willing to 
undergo screening assessment of the total number invited 
and of participants overall enrolled in the study out of 
the total number invited will be calculated with 95% CIs. 
To illustrate participant flow, we will report results in a 
CONSORT diagram. We will describe patients’ reasons 
for non-participation and numbers of enrolled practices 
by recruitment strategy. We will also analyse question-
naire outcome data (including NoMAD) descriptively. 
Qualitative data generated in the process evaluation will 
be subjected to thematic analysis which we will conduct 
in the qualitative data analysis software MAXQDA. Specif-
ically, we will derive key theme bottom-up. We will align 
all study publications with recommendations from state-
ments for observational and feasibility studies.
Patient and public involvement
This protocol was drafted without patient involvement. 
Patients were not consulted to develop patient-relevant 
outcomes or interpret the results. Patients were not invited 
to contribute to the writing or editing of this document 
for readability or accuracy. However, we did conduct focus 
groups with patient, MHS, GPs and medical assistants in 
primary care practices along with health policy-makers 
as part of pre-implementation study.51 52 Results from 
these focus groups significantly impacted on tailoring the 
intervention and the study procedures. We analysed and 
interpreted the results within two in-depth discussions 
within the study team. Main aspects and suggestions have 
been incorporated into the handbook for GPs and the 
study manual for MHS that provide guidance regarding 
the study procedures and the intervention. Examples 
which have been transferred from focus groups’ results 
are that (1) the appointment management were put into 
the hands of the MHS, (2) fixed time slots will be used 
and (3) each patient will continuously consult with the 
identical MHS.
EthICs And dIssEMInAtIon
Participants will be asked to provide informed consent 
prior to baseline assessment. In advance, they will receive 
detailed information about the study and their right to 
withdraw it without the obligation to give reasons. To 
adequately prepare for the emerging field of telemedicine, 
the study manual for MHS will be based on existing recom-
mendations for telepsychiatry.26 28–30 Moreover, MHS will 
be supported by a weekly supervision which will be led by 
a senior consultant both in psychiatry and psychosomatic 
medicine from the Department of General Internal Medi-
cine and Psychosomatics, Heidelberg University. This will 
help to react to unintended effects during the study. We 
do not expect major relevant risks for participants irrespec-
tive of phases of emotional arousal which frequently occur 
during psychotherapy. The time burden for the partici-
pants arising from the assessments will be of a reasonable 
amount. The data collection and storage will be conducted 
in accordance with the General Data Protection Regulation 
which ensures a high level of data safety and a conscien-
tious handling of all the patient, practice and therapist data. 
Additionally, considering that the study will take place in 
routine general practice, we obtained the ethical approval 
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of the State Chamber of Physicians Baden-Württemberg. As 
part of a wider dissemination, the results of this feasibility 
trial will inform the setup of a large-scale randomised trial 
which is supposed to evaluate broad regional implementa-
tion of MHSVC in primary care. Moreover, we will publish 
and present key outputs on conferences and in internation-
ally recognised peer-reviewed journals.
dIsCussIon
To the best of our knowledge, we conduct one of the first 
feasibility trials on mental health specialist video consul-
tations for patients with depression or anxiety disorders 
in European routine primary care. In more specific 
contexts, particularly in the USA, facilitating the inte-
gration of primary care and mental healthcare through 
video consultations has been shown to potentially over-
come geographical and temporal barriers in the search 
for specialised mental healthcare. As a low-threshold 
model embedded in a familiar environment, MHSVC 
in primary care may be of particular value for patients 
who are currently comparatively cut off from specialised 
care. This trial will deliver results on the feasibility of this 
model and prepare the ground for a fully powered RCT 
on its broader roll-out.
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